Details
Stereochemistry | ACHIRAL |
Molecular Formula | C16H20N4O3S |
Molecular Weight | 348.42 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)NC(=O)NS(=O)(=O)C1=CN=CC=C1NC2=CC(C)=CC=C2
InChI
InChIKey=NGBFQHCMQULJNZ-UHFFFAOYSA-N
InChI=1S/C16H20N4O3S/c1-11(2)18-16(21)20-24(22,23)15-10-17-8-7-14(15)19-13-6-4-5-12(3)9-13/h4-11H,1-3H3,(H,17,19)(H2,18,20,21)
DescriptionSources: http://www.drugbank.ca/drugs/DB00214Curator's Comment: Description was created based on several sources, including
http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020136s023lbl.pdf
Sources: http://www.drugbank.ca/drugs/DB00214
Curator's Comment: Description was created based on several sources, including
http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020136s023lbl.pdf
Torasemide is a pyridine-sulfonylurea type loop diuretic mainly used for the treatment of edema associated with congestive heart failure, renal disease, or hepatic disease. Also for the treatment of hypertension alone or in combination with other antihypertensive agents. It is also used at low doses for the management of hypertension. It is marketed under the brand name Demadex. Torasemide inhibits the Na+/K+/2Cl--carrier system (via interference of the chloride binding site) in the lumen of the thick ascending portion of the loop of Henle, resulting in a decrease in reabsorption of sodium and chloride. This results in an increase in the rate of delivery of tubular fluid and electrolytes to the distal sites of hydrogen and potassium ion secretion, while plasma volume contraction increases aldosterone production. The increased delivery and high aldosterone levels promote sodium reabsorption at the distal tubules, and by increasing the delivery of sodium to the distal renal tubule, torasemide indirectly increases potassium excretion via the sodium-potassium exchange mechanism. Torasemide's effects in other segments of the nephron have not been demonstrated. Thus torasemide increases the urinary excretion of sodium, chloride, and water, but it does not significantly alter glomerular filtration rate, renal plasma flow, or acid-base balance. Torasemide's effects as a antihypertensive are due to its diuretic actions. By reducing extracellular and plasma fluid volume, blood pressure is reduced temporarily, and cardiac output also decreases.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2095165 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21190426 |
1.0 µM [IC50] | ||
Target ID: CHEMBL2722 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26047574 |
|||
Target ID: GO:0001998 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10406837 |
0.5 µM [IC50] | ||
Target ID: CHEMBL1874 Sources: http://www.drugbank.ca/drugs/DB00214 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Demadex Approved UseDemadex is indicated for the treatment of edema associated with congestive heart failure, renal
disease, or hepatic disease. Use of torsemide has been found to be effective for the treatment of
edema associated with chronic renal failure.
Demadex is indicated for the treatment of hypertension alone or in combination with other
antihypertensive agents. Launch Date1993 |
|||
Primary | Demadex Approved UseDemadex is indicated for the treatment of edema associated with congestive heart failure, renal
disease, or hepatic disease. Use of torsemide has been found to be effective for the treatment of
edema associated with chronic renal failure.
Demadex is indicated for the treatment of hypertension alone or in combination with other
antihypertensive agents. Launch Date1993 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
968.7 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19673928 |
5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered: |
TORSEMIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
1549.9 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19673928 |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
TORSEMIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1561 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19673928 |
5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered: |
TORSEMIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
3516 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19673928 |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
TORSEMIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
4.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19673928 |
5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered: |
TORSEMIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
4.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19673928 |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
TORSEMIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1% |
10 mg 1 times / day multiple, oral dose: 10 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
TORSEMIDE unknown | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
400 mg 1 times / day multiple, oral Highest studied dose Dose: 400 mg, 1 times / day Route: oral Route: multiple Dose: 400 mg, 1 times / day Sources: Page: p.124 |
unhealthy Health Status: unhealthy Condition: Chronic renal failure Sources: Page: p.124 |
|
800 mg single, intravenous Highest studied dose Dose: 800 mg Route: intravenous Route: single Dose: 800 mg Sources: Page: p.124, 133 |
unhealthy Health Status: unhealthy Condition: Acute renal failure Sources: Page: p.124, 133 |
|
200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: Page: p.11 |
unhealthy Health Status: unhealthy Condition: Edema associated with congestive heart failure, renal disease, or hepatic disease Sources: Page: p.11 |
Disc. AE: Dizziness, Headache... AEs leading to discontinuation/dose reduction: Dizziness (0.1 - 0.5) Sources: Page: p.11Headache (0.1 - 0.5) Nausea (0.1 - 0.5) Weakness (0.1 - 0.5) Vomiting (0.1 - 0.5) Hyperglycemia (0.1 - 0.5) Urination abnormal NOS (0.1 - 0.5) Hyperuricemia (0.1 - 0.5) Hypokalemia (0.1 - 0.5) Excessive thirst (0.1 - 0.5) Hypovolemia (0.1 - 0.5) Impotence (0.1 - 0.5) Esophageal hemorrhage (0.1 - 0.5) Dyspepsia (0.1 - 0.5) |
200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: Page: p.6 |
unhealthy Health Status: unhealthy Condition: Edema associated with congestive heart failure, renal disease, or hepatic disease Sources: Page: p.6 |
Disc. AE: Electrolyte depletion, Electrolyte depletion... Other AEs: Hepatic coma, Tinnitus... AEs leading to discontinuation/dose reduction: Electrolyte depletion Other AEs:Electrolyte depletion Hypokalemia Hepatic coma Sources: Page: p.6Tinnitus Hearing loss |
200 mg 1 times / day multiple, intravenous Studied dose Dose: 200 mg, 1 times / day Route: intravenous Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy n = 44 Health Status: unhealthy Condition: Advanced chronic renal failure Population Size: 44 Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Dizziness | 0.1 - 0.5 Disc. AE |
200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: Page: p.11 |
unhealthy Health Status: unhealthy Condition: Edema associated with congestive heart failure, renal disease, or hepatic disease Sources: Page: p.11 |
Dyspepsia | 0.1 - 0.5 Disc. AE |
200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: Page: p.11 |
unhealthy Health Status: unhealthy Condition: Edema associated with congestive heart failure, renal disease, or hepatic disease Sources: Page: p.11 |
Esophageal hemorrhage | 0.1 - 0.5 Disc. AE |
200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: Page: p.11 |
unhealthy Health Status: unhealthy Condition: Edema associated with congestive heart failure, renal disease, or hepatic disease Sources: Page: p.11 |
Excessive thirst | 0.1 - 0.5 Disc. AE |
200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: Page: p.11 |
unhealthy Health Status: unhealthy Condition: Edema associated with congestive heart failure, renal disease, or hepatic disease Sources: Page: p.11 |
Headache | 0.1 - 0.5 Disc. AE |
200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: Page: p.11 |
unhealthy Health Status: unhealthy Condition: Edema associated with congestive heart failure, renal disease, or hepatic disease Sources: Page: p.11 |
Hyperglycemia | 0.1 - 0.5 Disc. AE |
200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: Page: p.11 |
unhealthy Health Status: unhealthy Condition: Edema associated with congestive heart failure, renal disease, or hepatic disease Sources: Page: p.11 |
Hyperuricemia | 0.1 - 0.5 Disc. AE |
200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: Page: p.11 |
unhealthy Health Status: unhealthy Condition: Edema associated with congestive heart failure, renal disease, or hepatic disease Sources: Page: p.11 |
Hypokalemia | 0.1 - 0.5 Disc. AE |
200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: Page: p.11 |
unhealthy Health Status: unhealthy Condition: Edema associated with congestive heart failure, renal disease, or hepatic disease Sources: Page: p.11 |
Hypovolemia | 0.1 - 0.5 Disc. AE |
200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: Page: p.11 |
unhealthy Health Status: unhealthy Condition: Edema associated with congestive heart failure, renal disease, or hepatic disease Sources: Page: p.11 |
Impotence | 0.1 - 0.5 Disc. AE |
200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: Page: p.11 |
unhealthy Health Status: unhealthy Condition: Edema associated with congestive heart failure, renal disease, or hepatic disease Sources: Page: p.11 |
Nausea | 0.1 - 0.5 Disc. AE |
200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: Page: p.11 |
unhealthy Health Status: unhealthy Condition: Edema associated with congestive heart failure, renal disease, or hepatic disease Sources: Page: p.11 |
Urination abnormal NOS | 0.1 - 0.5 Disc. AE |
200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: Page: p.11 |
unhealthy Health Status: unhealthy Condition: Edema associated with congestive heart failure, renal disease, or hepatic disease Sources: Page: p.11 |
Vomiting | 0.1 - 0.5 Disc. AE |
200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: Page: p.11 |
unhealthy Health Status: unhealthy Condition: Edema associated with congestive heart failure, renal disease, or hepatic disease Sources: Page: p.11 |
Weakness | 0.1 - 0.5 Disc. AE |
200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: Page: p.11 |
unhealthy Health Status: unhealthy Condition: Edema associated with congestive heart failure, renal disease, or hepatic disease Sources: Page: p.11 |
Hearing loss | 200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: Page: p.6 |
unhealthy Health Status: unhealthy Condition: Edema associated with congestive heart failure, renal disease, or hepatic disease Sources: Page: p.6 |
|
Hepatic coma | 200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: Page: p.6 |
unhealthy Health Status: unhealthy Condition: Edema associated with congestive heart failure, renal disease, or hepatic disease Sources: Page: p.6 |
|
Tinnitus | 200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: Page: p.6 |
unhealthy Health Status: unhealthy Condition: Edema associated with congestive heart failure, renal disease, or hepatic disease Sources: Page: p.6 |
|
Electrolyte depletion | Disc. AE | 200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: Page: p.6 |
unhealthy Health Status: unhealthy Condition: Edema associated with congestive heart failure, renal disease, or hepatic disease Sources: Page: p.6 |
Electrolyte depletion | Disc. AE | 200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: Page: p.6 |
unhealthy Health Status: unhealthy Condition: Edema associated with congestive heart failure, renal disease, or hepatic disease Sources: Page: p.6 |
Hypokalemia | Disc. AE | 200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: Page: p.6 |
unhealthy Health Status: unhealthy Condition: Edema associated with congestive heart failure, renal disease, or hepatic disease Sources: Page: p.6 |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
yes [Inhibition 100 uM] | ||||
yes [Inhibition 100 uM] | ||||
yes [Inhibition 100 uM] |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 9.0 |
minor | |||
Page: 9.0 |
minor | |||
Page: 5.0 |
yes | |||
yes |
PubMed
Title | Date | PubMed |
---|---|---|
Torasemide--a unique loop diuretic. | 2001 Apr-May |
|
Activity of a novel dual thromboxane A(2)receptor antagonist and thromboxane synthase inhibitor (BM-573) on platelet function and isolated smooth muscles. | 2001 Aug |
|
[Diuretics in heart failure. Can they also prolong life?]. | 2001 Dec 6 |
|
Simultaneous determination of torasemide and its major metabolite M5 in human urine by high-performance liquid chromatography-electrochemical detection. | 2001 Nov |
|
Optimal diuretic therapy for heart failure. | 2001 Nov |
|
Open-label randomized trial of torsemide compared with furosemide therapy for patients with heart failure. | 2001 Nov |
|
[Treatment of ascites in cirrhotic patients]. | 2001 Sep |
|
[A better diuretic for patients with heart failure. Better control of potassium loss]. | 2002 Aug 8 |
|
Crystal forms of torasemide: new insights. | 2002 Jan |
|
[Which loop diuretic for heart failure? For prognosis the choices are not all the same]. | 2002 Oct 3 |
|
Effects of acute renal failure induced by uranyl nitrate on the pharmacokinetics of intravenous torasemide in rats. | 2003 |
|
[Torasemide (Trifas) in clinical practice--own experience]. | 2003 |
|
Ethacrynic acid and the sulfa-sensitive patient. | 2003 Jan 13 |
|
[Favorable prognostic effect of heart failure therapy. Diuretic makes heart muscle more elastic]. | 2003 Jun 5 |
|
Effects of torasemide on left ventricular function and neurohumoral factors in patients with chronic heart failure. | 2003 May |
|
[Heart failure therapy. Cheap can become expensive]. | 2003 Oct 9 |
|
CYP2C9 polymorphisms and the interindividual variability in pharmacokinetics and pharmacodynamics of the loop diuretic drug torsemide. | 2004 Dec |
|
Torasemide inhibits transcardiac extraction of aldosterone in patients with congestive heart failure. | 2004 Dec 7 |
|
Regulatory considerations of pharmaceutical solid polymorphism in Abbreviated New Drug Applications (ANDAs). | 2004 Feb 23 |
|
Optimizing bacterial expression of catalytically active human cytochromes P450: comparison of CYP2C8 and CYP2C9. | 2004 Jan |
|
Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. | 2004 Jun 2 |
|
Differential contribution of active site residues in substrate recognition sites 1 and 5 to cytochrome P450 2C8 substrate selectivity and regioselectivity. | 2004 Jun 22 |
|
[Idiopathic hypereosinophilia with cardiac involvement]. | 2004 Mar 12 |
|
High-Dose Torasemide is Equivalent to High-Dose Furosemide with Hypertonic Saline in the Treatment of Refractory Congestive Heart Failure. | 2005 |
|
Screening procedure for detection of diuretics and uricosurics and/or their metabolites in human urine using gas chromatography-mass spectrometry after extractive methylation. | 2005 Aug |
|
[Aldosterone antagonist therapy for chronic heart failure]. | 2005 Feb 10 |
|
Dose-independent pharmacokinetics of torasemide after intravenous and oral administration to rats. | 2005 Jul |
|
Prediction of genotoxicity of chemical compounds by statistical learning methods. | 2005 Jun |
|
Comparison of the urine acidification tests of torsemide vs furosemide in healthy volunteers. | 2005 Nov |
|
Pharmacological profile and therapeutic potential of BM-573, a combined thromboxane receptor antagonist and synthase inhibitor. | 2005 Spring |
|
[A case of severe hyponatremia in a patient suffering from epilepsy and using oxcarbazepine]. | 2006 |
|
[Clinical efficacy and safety of administration of loop diuretic torasemide]. | 2006 |
|
Improved solid-phase extraction and HPLC measurement of torasemide and its important metabolites. | 2006 Feb 2 |
|
Probable loop diuretic-induced pancreatitis in a sulfonamide-allergic patient. | 2006 Jan |
|
Cardiomyopathy, familial dilated. | 2006 Jul 13 |
|
Gemcitabine in combination with EGF-Receptor antibody (Cetuximab) as a treatment of cholangiocarcinoma: a case report. | 2006 Jul 17 |
|
Dose-dependent association between use of loop diuretics and mortality in advanced systolic heart failure. | 2006 Nov 15 |
|
Efficacy and safety of a furosemide continuous infusion following cardiac surgery. | 2006 Oct |
|
Torsemide renal clearance and genetic variation in luminal and basolateral organic anion transporters. | 2006 Sep |
|
Hospital policies for treatment of acute decompensated heart failure. | 2007 Apr |
|
Gender difference in the pharmacokinetic interaction between oral warfarin and oxolamine in rats: inhibition of CYP2B1 by oxolamine in male rats. | 2007 Apr |
|
Torasemide transport by organic anion transporters contributes to hyperuricemia. | 2007 Dec |
|
Vasodilatory action of loop diuretics: a plethysmography study of endothelial function in forearm arteries and dorsal hand veins in hypertensive patients and controls. | 2007 Feb |
|
Effect of torsemide on serum and urine electrolyte levels in dogs with congestive heart failure. | 2007 Jun 16 |
|
Loop diuretics in the management of acute renal failure: a systematic review and meta-analysis. | 2007 Mar |
|
Genetic variation in the renal sodium transporters NKCC2, NCC, and ENaC in relation to the effects of loop diuretic drugs. | 2007 Sep |
|
Secondary pulmonary hypertension: haemodynamic effects of torasemide versus furosemide. | 2008 |
|
Comparative effects of torasemide and furosemide in rats with heart failure. | 2008 Feb 1 |
|
Torasemide, a long-acting loop diuretic, reduces the progression of myocarditis to dilated cardiomyopathy. | 2008 Feb 26 |
|
The polymorphisms Asn130Asp and Val174Ala in OATP1B1 and the CYP2C9 allele *3 independently affect torsemide pharmacokinetics and pharmacodynamics. | 2008 Jun |
Patents
Sample Use Guides
Congestive Heart Failure
The usual initial dose is 10 mg or 20 mg of once-daily oral Demadex (Torasemide). If the diuretic response is inadequate, the dose should be titrated upward by approximately doubling until the desired diuretic response is obtained. Single doses higher than 200 mg have not been adequately studied.
Chronic Renal Failure
The usual initial dose of Demadex is 20 mg of once-daily oral Demadex.
Hypertension
The usual initial dose is 5 mg once daily. If the 5 mg dose does not provide adequate reduction in blood pressure within 4 to 6 weeks, the dose may be increased to 10 mg once daily.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10406837
Isometric contraction induced by a submaximal concentration of Ang II (10(-7) mol/L) was reduced in a dose-dependent way by torasemide (IC(50)=0.5+/-0.04 umol/L) in cultured vascular smooth muscle cells (VSMCs) from spontaneously hypertensive rats..
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Official Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QC03CA04
Created by
admin on Fri Dec 15 15:31:48 GMT 2023 , Edited by admin on Fri Dec 15 15:31:48 GMT 2023
|
||
|
LIVERTOX |
984
Created by
admin on Fri Dec 15 15:31:48 GMT 2023 , Edited by admin on Fri Dec 15 15:31:48 GMT 2023
|
||
|
WHO-ATC |
C03CA04
Created by
admin on Fri Dec 15 15:31:48 GMT 2023 , Edited by admin on Fri Dec 15 15:31:48 GMT 2023
|
||
|
NDF-RT |
N0000175366
Created by
admin on Fri Dec 15 15:31:48 GMT 2023 , Edited by admin on Fri Dec 15 15:31:48 GMT 2023
|
||
|
NCI_THESAURUS |
C49184
Created by
admin on Fri Dec 15 15:31:48 GMT 2023 , Edited by admin on Fri Dec 15 15:31:48 GMT 2023
|
||
|
EMA VETERINARY ASSESSMENT REPORTS |
UPCARD [AUTHORIZED]
Created by
admin on Fri Dec 15 15:31:48 GMT 2023 , Edited by admin on Fri Dec 15 15:31:48 GMT 2023
|
||
|
NDF-RT |
N0000175590
Created by
admin on Fri Dec 15 15:31:48 GMT 2023 , Edited by admin on Fri Dec 15 15:31:48 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1672304
Created by
admin on Fri Dec 15 15:31:48 GMT 2023 , Edited by admin on Fri Dec 15 15:31:48 GMT 2023
|
PRIMARY | |||
|
TORASEMIDE
Created by
admin on Fri Dec 15 15:31:48 GMT 2023 , Edited by admin on Fri Dec 15 15:31:48 GMT 2023
|
PRIMARY | |||
|
C29506
Created by
admin on Fri Dec 15 15:31:48 GMT 2023 , Edited by admin on Fri Dec 15 15:31:48 GMT 2023
|
PRIMARY | |||
|
DB00214
Created by
admin on Fri Dec 15 15:31:48 GMT 2023 , Edited by admin on Fri Dec 15 15:31:48 GMT 2023
|
PRIMARY | |||
|
W31X2H97FB
Created by
admin on Fri Dec 15 15:31:48 GMT 2023 , Edited by admin on Fri Dec 15 15:31:48 GMT 2023
|
PRIMARY | |||
|
56211-40-6
Created by
admin on Fri Dec 15 15:31:48 GMT 2023 , Edited by admin on Fri Dec 15 15:31:48 GMT 2023
|
PRIMARY | |||
|
2708
Created by
admin on Fri Dec 15 15:31:48 GMT 2023 , Edited by admin on Fri Dec 15 15:31:48 GMT 2023
|
PRIMARY | |||
|
CHEMBL1148
Created by
admin on Fri Dec 15 15:31:48 GMT 2023 , Edited by admin on Fri Dec 15 15:31:48 GMT 2023
|
PRIMARY | |||
|
SUB11195MIG
Created by
admin on Fri Dec 15 15:31:48 GMT 2023 , Edited by admin on Fri Dec 15 15:31:48 GMT 2023
|
PRIMARY | |||
|
C026116
Created by
admin on Fri Dec 15 15:31:48 GMT 2023 , Edited by admin on Fri Dec 15 15:31:48 GMT 2023
|
PRIMARY | |||
|
7312
Created by
admin on Fri Dec 15 15:31:48 GMT 2023 , Edited by admin on Fri Dec 15 15:31:48 GMT 2023
|
PRIMARY | |||
|
9637
Created by
admin on Fri Dec 15 15:31:48 GMT 2023 , Edited by admin on Fri Dec 15 15:31:48 GMT 2023
|
PRIMARY | |||
|
38413
Created by
admin on Fri Dec 15 15:31:48 GMT 2023 , Edited by admin on Fri Dec 15 15:31:48 GMT 2023
|
PRIMARY | RxNorm | ||
|
3938
Created by
admin on Fri Dec 15 15:31:48 GMT 2023 , Edited by admin on Fri Dec 15 15:31:48 GMT 2023
|
PRIMARY | |||
|
DTXSID2023690
Created by
admin on Fri Dec 15 15:31:48 GMT 2023 , Edited by admin on Fri Dec 15 15:31:48 GMT 2023
|
PRIMARY | |||
|
100000090291
Created by
admin on Fri Dec 15 15:31:48 GMT 2023 , Edited by admin on Fri Dec 15 15:31:48 GMT 2023
|
PRIMARY | |||
|
41781
Created by
admin on Fri Dec 15 15:31:48 GMT 2023 , Edited by admin on Fri Dec 15 15:31:48 GMT 2023
|
PRIMARY | |||
|
m10981
Created by
admin on Fri Dec 15 15:31:48 GMT 2023 , Edited by admin on Fri Dec 15 15:31:48 GMT 2023
|
PRIMARY | Merck Index | ||
|
Torsemide
Created by
admin on Fri Dec 15 15:31:48 GMT 2023 , Edited by admin on Fri Dec 15 15:31:48 GMT 2023
|
PRIMARY | |||
|
W31X2H97FB
Created by
admin on Fri Dec 15 15:31:48 GMT 2023 , Edited by admin on Fri Dec 15 15:31:48 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)